| Literature DB >> 32762695 |
Efat Mohamadi1, Amirhossein Takian1,2,3, Alireza Olyaeemanesh4,5, Arash Rashidian2,6, Ali Hassanzadeh7, Moaven Razavi8, Sadegh Ghazanfari2.
Abstract
BACKGROUND: Insufficient transparency in prioritization of health services, multiple health insurance organizations with various and not-aligned policies, plus limited resources to provide comprehensive health coverage are among the challenges to design appropriate Health Insurance Benefit Package (HIBP) in Iran. This study aims to analyze Policy Process of Health Insurance Benefit Package in Iran.Entities:
Keywords: Benefit package; Health insurance; Iran; Policy process analysis
Mesh:
Year: 2020 PMID: 32762695 PMCID: PMC7409638 DOI: 10.1186/s12913-020-05592-w
Source DB: PubMed Journal: BMC Health Serv Res ISSN: 1472-6963 Impact factor: 2.655
Fig. 1Conceptual framework of policy process analysis of HIBP in Iran
Policy “process” Analysis of HIBP
| Issues | Themes | Sub-themes | |
|---|---|---|---|
| Agenda setting | Problem stream | 1. Increasing the number of services that can be provided 2. Soaring health expenditures 3. Unavailability of information about inequality within insured populations 4. Inadequacy of resources 5. 5. Parallel budgets (insurances, hygiene, special programs, etc.) | |
| Policies stream | 6. Managing services that can be provided 7. Deficiencies in legislation and decision-making process that are related to the HIBP 8. Lack of clear criteria for including services in the HIBP 9. Not using professional and related staffs (not only those who are experienced) in implementation and support of the HIBP | ||
| Politics stream | 10. Prioritizing health, and therefore its related policies, in the twelfth government 11. Increasing health sector budget in the 11th government 12. 13. Notifying OHP and making decision about the HIBP | ||
| Policy development | Stewardship of the policy making | 13. Developing the article 29 of the constitution 14. Developing policy’s draft by the MoHME and MoCLSW 15. HCHI as the steward of developing and notifying the HIBP’s strategies 16. Confirming policies by the National Expediency Council 17. Enacting policies by the Parliament 18. Final approval and notifying OHP by the supreme leader’s office 19. The MoHME is the steward of developing the HIBP based on the OHP | |
| Method and trend of decision-making | 20. Endorsing the HIBP by the third NDP for the first time 21. Lack of a defined methodology to include/exclude services into/from the HIBP 22. Drafted policies are different from notified policies, up to 70% 23. The ISCHI makes decision about the strategic policies of the HIBP 24. Developing polices according to the available resources 25. A defined contribution approach in developing HIBP-related policies 26. Inadequate attention to people’s preference/demand 27. 28. Using a top-down approach in developing HIBP-related policies in OHP | ||
| Policy implementation | Policy implementation timeline | Before 1993 | 28. Article 29 of the constitution, requires the government to cover all necessary services 29. Lack of a clear distinction between service provision in public and private sectors 30. Lack of defined criteria to cover services by health insurance organizations 31. 33. Considering the availability of services when deciding to provide a service |
| Between 1993 to 2003 | 32. Developing the UHI Act in 1993 and notifying it in 1994 33. Establishing the HCHI within the MoHME 34. HCHI became responsible about the HIBP 35. Experts debating in joint meetings 36. Commitment to provide all services that can be provided 37. Determining the covered services by the health insurance organizations 38. Political top-down decisions, without expert debates 39. Stakeholders or head of the meeting have greater influence | ||
| 2004 to 2006 | 40. Transferring the ISCHI from the MoHME to the MoCLSW 41. Insurance-related stakeholders had more influence 42. Services/medicines were included based on the frequency and compensation patterns 43. Including Services/medicines based on the reviewing less expensive services and equipment 44. Top-down political decisions, without expert debates 45. Introducing complementary insurance to cover services that were not covered by the basic insurance | ||
| 2007 to 2014 | 46. Developing the first comprehensive package 47. Using the most frequent services criterion to develop the HIBP 48. It takes a long time to decide whether to include a service/medicine or not 49. HCHI decides based on the consensus criteria 50. Special packages or separate resources/stewards (e.g. special diseases) 51. In 2010, the MoHME and the MoCLSW started strategic purchasing 52. New mandatory criteria were introduced (i.e. safety studies, effectiveness, cost-effectiveness) to include new medicines to the national formulary 53. In 2012, new RVU Book was developed | ||
| Since 2014 | 54. In 2014, the OHP were notified by the Supreme Leader’s office 55. In 2014, the MoHME was mandated to develop the new HIBP 56. The MoCLSW was selected as the steward of financing and implementing the HIBP 57. In 2014, health transformation plan was started 58. The new HIBP was defined in the form of the RVU Book 59. Services that are not included in the HIBP were clearly mentioned in the new RVU Book 60. Defining and providing services that were not previously covered in the HIBP, as a part of the HTP | ||
| Process of HIBP implementation | 61. Sending a request to the ISCHI 62. Expert review of the request 63. Deciding about the request 64. If it has low financial burden, notifying its inclusion to the HIBP 65. If it has high financial burden, the cabinet confirmation is required | ||
| Evaluation | HIBP Revision | 66. Lack of fundamental and purposive revision(s) 67. Before 2014, there was no significant change occurred in the HIBP 68. Due to changes in the treatment methods, some services/drugs are automatically excluded 69. Mandating the ISCHI to annually revise the HIBP 70. Temporary and non-methodological changes (three times, in 2007, 2012, and 2014) 71. Unorganized revision of the OTC drugs 72. In 2003, some performance-enhancing drugs were excluded | |
| Revising the methods and decisions | 73. Process and criteria for including/excluding services are not revised 74. No evaluation has been performed, and laws and regulations are not revised 75. In 2013, service prioritizing program was begun, without clear outcomes | ||
| Evaluating the aims of HIBP-related policies | 76. The impact of HIBP-related policies on achieving universal health insurance coverage 77. The impact of HIBP-related policies on developing basic and complementary HIBPs 78. The impact of HIBP-related policies on unifying the HIBP among all health insurance organizations | ||
Limitations and problems of the HIBP policy process
• Lack of clear criteria to include services into the HIBP • Not considering the epidemiological transitions to increase the effectiveness of included services. • Scientific evidences were not adequately used • Health Technology Assessment (HTA) studies were not used • Bargaining power had an important role in the ISCHI decisions • The extensive HIBP list regardless of the priorities and costs • Policies on HIBP and the strategic purchasing were not implemented • Cultural, social and economic issues were not considered • Passive performance of health insurance organizations to include new proposed services within the HIBP • Lack of revision and evaluation systems • OTC drugs are included in the HIBP • Unproportioned percentage of the health expenditures are created by a small percentage of patients • Development and implementation of programs and policies are not permanent • Inadequate resources |
Solutions and policy options derived from the policy process analysis for the HIBP
| Solutions | Policy options/description | Pros | Cons | Average Necessity and feasibility (+_) standard deviation (1–10) |
|---|---|---|---|---|
| Differentiating between HIBP(s) from services that can be provided | Defining necessary services benefit package and financing it by government and defining the higher level package that its financing is elective | Creating elective options for patients/ people and financial savings for the government | Establishing limitations on access to higher level services | 7.8 ± 1 |
| Defining “necessary primary services HIBP” and financing it by the MoHME and also a “HIBP for secondary and tertiary necessary services” and financing it by insurance organizations | Ensure easy and free access to primary services, more effective management of curative services with stewardship of health insurance organizations | Inadequate attention of insurance organizations to the importance of preventive and screening services | 5 ± 2.55 | |
| Developing a HIBP that can be provided in all levels and financing it by health insurance organizations | Matching the HIBP with society’s health needs | Probability of increasing the number of covered services without considering available resources of health insurance organizations has increased | 5.3 ± 2.3 | |
| Using scientific evidences to make HIBP-related decisions | Collecting and reviewing demographic information | Prioritizing services and evidence-based decision-making, indeed the HIBP should be targeted | Lack of precise information systems to determine the burden and pattern of diseases, by age groups | 7.6 ± 1.5 |
| Conducting HTA studies | Developing a cost effective HIBP based on the comprehensive needs | These studies are cost driven and adequate experts to conduct them are not available | 6.9 ± 1.6 | |
| Considering cultural problems and needs in developing the HIBP (i.e. religious beliefs and cultural behaviors) | Increasing the acceptability of services for targeted populations, increasing equity in health | Increasing the probability of health expenditure soaring for the health system | 4.6 ± 1.7 | |
| Considering intervention’s QALY and DALY (analyzing the epidemiologic profile, and determining interventions based on it) | Prioritizing services that have more influence on life expectancy and quality of life | Ethical and social criteria are neglected | 6.7 ± 1 | |
| Estimating the financial burden of diseases | Direct, indirect and intangible costs | Creating a systemic view or considering costs carried out by patients and avoiding catastrophic expenditures | Ignoring the necessity of covering some services that based on economic terms should not be covered | 6.6 ± 1.6 |
| Employing multi-criteria decision-making methods to develop the HIBP | Considering criteria that are related to economic aspects of services (cost effectiveness, budget impact, reducing poverty, quality and quantity of evidences and equity in better access to health-care services | More economic mix of services and avoiding exorbitant costs; transparency of definitions and prioritizing economic criteria | Some decision have unethical economic consequences | 7.6 ± 1.1 |
| Mixing cost and effectiveness and economic and socio-economic criteria in related decisions (using multi-criteria decisions) | Creating a comprehensive view or considering all criteria that affects the decisions; increasing cost-effectiveness of the HIBP | Collecting information is time-consuming, and such decisions are costly | 7.9 ± 1 | |
| Controlling inclusion of drugs, services and equipment that their effectiveness is not proved | The MoHME’s intervention in licensing new drugs and technologies or developing and implementing laws and regulations to restrict and control them | Increasing the control over services that can be provided, and, therefore, preventing the inclusion of services that are not cost effectiveness | A prolonged period is required to update health services of the country | 8 ± 1.1 |
| Organizing services/ drugs list that are covered or not covered | Developing a waiting list to include/exclude services/drugs (due to technological changes, policy change, new diseases patterns) | More efficient management of decisions to include/exclude services/drugs and facilitating annual revisions | More health human resources as well as continuous monitoring are required | 8 ± 0.7 |
| Creating a decision-making framework based on mathematical models and defined criteria | Weighting predetermined criteria and determining how to mix them by mathematical models | Transparency of method and process of decision-making and determining weights of criteria to make decisions | Possibility of conflict with ethical values in decision’s outcomes | 6.7 ± 1 |
| Expanding the package of services that can be provided | Expanding the HIBP by providing extra resources | Increasing access to health-care services | Services utilization is out of control and is creating exorbitant costs | 5.8 ± 1.3 |
| Expanding the HIBP along with developing guidelines and standards for services provision | Increasing cost-effectiveness of services, reducing induced demand | Access to services can potentially be decreased | 7 ± 1.2 | |
| Expanding the HIBP along with developing specialized packages for each level of the health system | Increasing cost -effectiveness of services, reducing induced demand | Access to services can potentially be decreased | 7.7 ± 1.2 | |
| Policies should be based on study’s findings and expert’s opinions | Macro decisions be made at higher levels and following that performing expert studies to increase efficacy of implementation | Clear tasks of middle and lower levels, converging tasks at lower levels | Environmental problems and issues are not reflected in macro decisions | 7 ± 1.2 |
| Proposing policies by expert level and following that developing and notifying policies at macro level | Developing evidence-based policies | Prolonging decision-making process | 7.3 ± 1.2 | |
| Determining macro-level decisions orientation and following that developing expert-based policies | Transparency of overall strategies and finally making evidence-based decisions | Possibility of different interpretations that may be different from macro policies | 7.9 ± 1.3 | |
| Organizing ISCHI meeting on including/excluding a service/drug/ equipment | Developing specialized forms which contain key criteria such as cost-effectiveness | Increasing efficacy of decisions through systematic process and defined participation of stakeholders | Challenges may arise in exceptional cases | 8.3 ± 1 |
| Revision and evaluation of the HIBP, both services-and- drugs related | Categorizing services/ drugs in three different lists (i.e. must be under coverage, can be covered, and must not be covered). Then, conducting cost-effectiveness studies for those services that can be covered | Making the HIBP cost-effective by spending minimum time and cost | HTA studies are not performed for all services; categorization may be biased | 7.9 ± 1.3 |
| Conducting HTA studies for all services/drugs that can be provided, then revising the HIBP | Having a HIBP with cost-effective services, as much as possible | HTA studies are highly time and cost consuming; social criteria may be neglected | 6.1 ± 1.6 | |
| Perform the first method for the services in the package and the requirement for the HTA to include the new services / drug into the package | The HIBP will be cost-effective; these studies will be institutionalized in deciding about including services/ drugs | HTA studies are not performed for all services; categorization may be biased | 7.5 ± 1.1 | |
| Conducting second method and mandating HTA studies | Having a HIBP with highest possible of cost-effective services/drugs; these studies will be institutionalized in deciding about including services/ drugs | HTA studies are highly time and cost consuming; social criteria may be neglected | 6.6 ± 1.8 | |
| Determining the minimum expected level of health with measurable indicators to identify the situation or measuring the gap between coverage level and defined standards | Developing the HIBP based on the country’s needs | Lack of scientific evidences and field studies; conducing required studies require extra resources | 5.8 ± 1.7 |